Cargando…

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC

INTRODUCTION: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (IC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibson, Amanda J.W., Pabani, Aliyah, Dean, Michelle L., Martos, Guillermo, Cheung, Winson Y., Navani, Vishal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006852/ https://www.ncbi.nlm.nih.gov/pubmed/36915629 http://dx.doi.org/10.1016/j.jtocrr.2022.100460

Ejemplares similares

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
por: Watson, Alexander S., et al.
Publicado: (2022)

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC
por: Johnson, Bruce E., et al.
Publicado: (2022)

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
por: O’Sullivan, Dylan E., et al.
Publicado: (2022)

430 Patients with Prolonged (>10 days) Neutropenia Displayed Similar IFI Rates Regardless of Hematologic Diagnosis and Chemotherapy Status: A Challenge to Antifungal Prophylaxis Decisions
por: Saxinger, Lynora, et al.
Publicado: (2014)

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
por: Perrotta, Fabio, et al.
Publicado: (2019)

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
por: Zhang, Chenxing, et al.
Publicado: (2020)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
por: Gibson, Amanda J.W., et al.
Publicado: (2021)

BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
por: Cen, Shuyi, et al.
Publicado: (2021)

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations
por: Garassino, Marina C., et al.
Publicado: (2023)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
por: Morimoto, Kenji, et al.
Publicado: (2022)

Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective
por: Wills, Allison, et al.
Publicado: (2023)

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study
por: Manzano, José L., et al.
Publicado: (2023)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors
por: Samnani, Sunil, et al.
Publicado: (2023)

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
por: Kartolo, Adi, et al.
Publicado: (2022)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3mo86ol1hadktk9cq5kmgs4t0p